Completed PHASE4 INTERVENTIONAL 2-arm NCT00140465

75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)

A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)

Sponsor: Deutsches Herzzentrum Muenchen

Conditions Coronary Disease

Interventions Clopidogrel

Updated 6 times since 2017 Last updated: Nov 13, 2007 Started: Oct 31, 2004 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00140465, this PHASE4 trial focuses on Coronary Disease and remains completed. Sponsored by Deutsches Herzzentrum Muenchen, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Nov 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Nov 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Deutsches Herzzentrum Muenchen
Technical University of Munich

Data source: Deutsches Herzzentrum Muenchen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany